key: cord-0710708-ysnq44ls authors: Mitaka, Hayato; Perlman, David C.; Javaid, Waleed; Salomon, Nadim title: Putative invasive pulmonary aspergillosis in critically ill patients with COVID‐19: An observational study from New York City date: 2020-10-01 journal: Mycoses DOI: 10.1111/myc.13185 sha: cbb3fec1a500fe8c14e96c20f71544cd18670a04 doc_id: 710708 cord_uid: ysnq44ls BACKGROUND: Critically ill patients with coronavirus disease‐2019 (COVID‐19) are at the theoretical risk of invasive pulmonary aspergillosis (IPA) due to known risk factors. PATIENTS/METHODS: We aimed to describe the clinical features of COVID‐19‐associated pulmonary aspergillosis at a single centre in New York City. We performed a retrospective chart review of all patients with COVID‐19 with Aspergillus isolated from respiratory cultures. RESULTS: A total of seven patients with COVID‐19 who had one or more positive respiratory cultures for Aspergillus fumigatus were identified, all of whom were mechanically ventilated in the ICU. Four patients were classified as putative IPA. The median age was 79 years, and all patients were male. The patients had been mechanically ventilated for a mean of 6.8 days (range: 1‐14 days) before Aspergillus isolation. Serum galactomannan level was positive for only one patient. The majority of our cases received much higher doses of glucocorticoids than the dosage with a proven mortality benefit. All four patients died. CONCLUSIONS: Vigilance for secondary fungal infections will be needed to reduce adverse outcomes in critically ill patients with COVID‐19. Invasive pulmonary aspergillosis (IPA) has been reported in critically ill patients in the ICU. 1, 2 Patients with coronavirus disease-2019 (COVID-19) may develop acute hypoxemic respiratory failure and are at high risk of requiring mechanical ventilation with prolonged ICU stays. Further, patients with severe COVID-19 may be administered high-dose glucocorticoids. Hence, there is a theoretical risk of IPA in patients with COVID-19 due to combined known risk factors. However, there are scant data on aspergillosis in patients with COVID-19. [3] [4] [5] [6] The aim of the study was to describe the clinical features of critically ill COVID-19-infected patients with pulmonary aspergillosis at a New York City hospital. We performed a retrospective chart review of all COVID-19-infected patients with Aspergillus isolates in respiratory samples during 21 March and 22 April 2020 at Mount Sinai Beth Israel, an acute care hospital in New York City. We collected longitudinal clinical data, including fraction of inspired oxygen (FiO 2 ) and vital signs, laboratory and microbiology data, treatment, and outcomes. Serial chest radiographs and computed tomography (CT) scans were reviewed. Glucocorticoid dose was converted into an equivalent dose of prednisone. Fever was defined as a temperature of ≥100.4 Fahrenheit. We used the clinical algorithm for ICU patients to classify pulmonary aspergillosis as either putative IPA or colonisation (AspICU algorithm). 7 As per the clinical algorithm, persistent fever was defined as fever persisting despite at least 3 days of antibiotic therapy or recrudescent fever while on antibiotics without other apparent cause. Worsening respiratory status was defined by an increase in FiO 2 requirement on mechanical ventilation, or worsening respiratory failure led to invasive mechanical ventilation. Study approval was obtained from the institutional review board of the Icahn School of Medicine at Mount Sinai. A total of seven patients with COVID-19 who had one or more positive respiratory cultures for Aspergillus fumigatus were identified. According to the AspICU algorithm, 7 Only one patient had a pre-existing lung disease (chronic obstructive pulmonary disease in Patient 1). All four patients had compatible signs (fever refractory to at least 3 days of appropriate therapy or worsening respiratory insufficiency despite appropriate antibiotic therapy and ventilatory support), host factor (glucocorticoid treatment with prednisone equivalent > 20 mg/d) and abnormal ra- Table 1 . The median age was 79 years. All experienced worsening respiratory status leading to invasive mechanical ventilation before the isolation of Aspergillus fumigatus. The patients had been mechanically ventilated for a mean of 6.8 days (range: 1-14 days) before Aspergillus isolation. At Aspergillus isolation, fever and leukocytosis were present in one and all four patients, respectively. Serum galactomannan level was positive for only one patient (Patient 2). All patients received concomitant broad-spectrum antibiotic therapy. All four patients concomitantly received glucocorticoids, with three of which were already given steroids for a mean of 6.6 days (range: 5-8 days) before the isolation of Aspergillus. In the remaining one patient (patients 4), glucocorticoid therapy was ad- to define the incidence and clinical features of COVID-19-associated pulmonary aspergillosis (CAPA). 8 Serum galactomannan was positive in only one patient in our case series. Serum galactomannan is more specific for invasive aspergillosis than beta-D-glucan but has poor sensitivity in non-neutropenic patients. 12 Combining three case series of CAPA, only three (13%) out of 23 patients had positive serum galactomannan level. 5, 6, 13 The less frequently elevated serum galactomannan levels might simply reflect colonisation rather than infection or suggest that angioinvasive pulmonary infection is a rare phenomenon in CAPA. In any case, the diagnostic value of serum galactomannan for CAPA seems less promising. There are no conflicts of interest to declare. writing-review and editing (equal). Waleed Javaid: Supervision (equal); writing-review and editing (supporting). Nadim Salomon: Conceptualization (equal); data curation (equal); investigation (equal); methodology (equal); supervision (equal); writing-original draft (supporting); writing-review and editing (equal). The data that support the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy or ethical restrictions. https://orcid.org/0000-0003-0765-3955 Waleed Javaid https://orcid.org/0000-0002-1213-4677 Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient COVID-19-associated pulmonary aspergillosis COVID-19 associated pulmonary aspergillosis Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19 A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients Invasive aspergillosis as an under-recognized superinfection in COVID-19 The role of procalcitonin in the identification of invasive fungal infection-a systemic review and meta-analysis Prevention of healthcare-associated invasive aspergillosis during hospital construction/renovation works Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan Dexamethasone in hospitalized patients with Covid-19 -preliminary report Putative invasive pulmonary aspergillosis in critically ill patients with COVID-19: An observational study from New York City